UroGen Pharma
Latest round
- Series A
Last raised
- Nov 2015
Total raised
- $18M
Investors
- 1
About UroGen Pharma
UroGen Pharma Ltd.Founded in 2004 in Princeton, US, UroGen Pharma Ltd. specializes in urological cancer therapies. The company had a significant strategic pivot towards developing FDA-approved products. Liz Barrett currently serves as CEO.UroGen Pharma specializes in the development and commercialization of innovative therapeutics for urological cancers, focusing on non-muscle invasive bladder cancer. Their flagship product, ZUSDURI™ (mitomycin), is an FDA-approved intravesical solution for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Additionally, UroGen’s Jelmyto® (mitomycin) for pyelocalyceal solution utilizes proprietary RTGel® technology and is the first FDA-approved treatment utilizing this novel platform. These products aim to meet significant medical needs by providing effective treatment options that enhance patient quality of life.40 mn.66 mn for the same period. UroGen Pharma's revenue comes from the sale of its therapeutics, ZUSDURI™ and Jelmyto®, sold primarily to healthcare providers and specialty pharmacies in the United States. The company maintains direct-to-consumer transactions and partnerships with healthcare institutions prescribing their products for specific urological cancers.00 mn to support the development and launch of new therapeutic products targeting additional urological cancer indications. The company is targeting expansion into international markets, with plans to enter regions such as Europe and Asia by 2025. This growth strategy will build on their current product offerings and aims to enhance their global presence in the urological oncology space.
Who invested in UroGen Pharma
1 investor across 1 round
See all investors in UroGen Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 16, 2015
Amount
$18M
Investors
Questions about UroGen Pharma
Who invested in UroGen Pharma?
UroGen Pharma has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has UroGen Pharma raised?
UroGen Pharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did UroGen Pharma last raise money?
UroGen Pharma's most recent round on record is a Series A, in Nov 2015.
What does UroGen Pharma do?
UroGen Pharma is a biotechnology company.
Where is UroGen Pharma headquartered?
UroGen Pharma is headquartered in Princeton, US.
Which VCs invest in companies like UroGen Pharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at UroGen Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like UroGen Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.